Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

revealed dose-related increases in exposure to ITI-007 and two metabolites with increasing dose.

These robust improvements in sleep suggest that ITI-007 will have utility in treating not only sleep maintenance insomnia but also other disorders associated with fragmented sleep including many neuropsychiatric (e.g. major depression, bipolar disorder, PTSD, mild cognitive impairment and schizophrenia) and neurological diseases (e.g. Parkinson's and Alzheimer's diseases).

ABOUT SLEEP MAINTENANCE DISORDERS

From insomnia to sleep apnea, sleep disorders disrupt the sleep of millions of people all over the world. In particular, about 20% to 30% of the U.S. population complains of waking up frequently during the night or too early several times a week, symptoms of SMI that are characterized by difficulty staying asleep and unrefreshing sleep. In many populations (e.g. the elderly) the majority of sleep complaints are related to SMI rather than sleep initiation or difficulty in falling asleep. In addition, this type of sleep disruption is common in patients with depression, bipolar disorder and other mood disorders, Alzheimer's disease (AD) and neurological disorders. For example, sleep disturbances in patients with Alzheimer's disease is one of the primary reasons that persons with AD are institutionalized. There is a significant need for sleep medications that improve sleep in patients with neuropsychiatric and neurologic disorders and comorbid sleep disorders.

ABOUT ITI-007

ITI-007 is the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia. ITI-007 has dual properties; it acts as a post-synaptic antagonist and as a pre-synaptic partial agonist. The combination of ITI-007's high-potency blockade of 5HT2A receptors and unique dopamine receptor activity should allow a personalized a
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   Intrexon Corporation ... first quarter 2015 financial results after the market closes ... conference call that day at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Conference Call."  Participants may also ...
(Date:5/1/2015)... OncoTAb, Inc., a University of North ... Pinku Mukherjee, Ph.D. has received the O. Max ... faculty honor. Mukherjee received the award, which recognizes ... research and development of cancer diagnostics and treatments. , ... in my scientific career,” said Mukherjee, OncoTAb Co-founder and ...
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... ) announced today that Roger Jeffs , Ph.D., President ... overview and update on the company,s business at the Deutsche ... Boston, Massachusetts . The presentation will ... Eastern Time, and can be accessed via a live webcast ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... Middle East,s only forum for the global pharma/biotech industries, Pharmaceutical Manufacturing ... ... April 2008, DUBAI, United Arab Emirates, Sept. 4 The Middle ... and with annual growth in double digits. The market,drivers are: -- ...
... Exists Between Understanding Cholesterol Monitoring Versus ... N.J., Sept. 4, 2007 A recent survey ... spite of concerns about the,serious health risks associated ... coronary heart disease, there is a significant disconnect,between ...
... Calif., Sept. 4 Volcano,Corporation (Nasdaq: VOLC ... measurement (FM) products designed to enhance the diagnosis,and ... today that it,will be participating in the Bear ... The presentation by Scott Huennekens, president and chief ...
Cached Biology Technology:New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 2New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 3New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 4New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 5New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 6New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 7Volcano Corporation Presentation at Bear Stearns Conference to be Webcast 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... French . , Two McGill researchers have ... Fellowships. Dr. Andrew P. Hendry an associate professor with ... Dr. Karim Nader, an associate professor and Willam Dawson ... the prestigious fellowships from the Natural Sciences and Engineering ...
... emotional toll on our bodies and scientists are working on ... to stress at the cellular level in the brain. ... essential for survival. Using a rat model, Jaideep ... of researchers at the Hotchkiss Brain Institute have discovered that ...
... for pregnant women and their children, and vitamin B12 ... any common multivitamin, say doctors and dietitians with the ... are available for comment in response to a new ... vitamin B12 may increase the risk for neural tube ...
Cached Biology News:2 McGill researchers garner prestigious NSERC Steacie Fellowships 2New and unexpected mechanism identified how the brain responds to stress 2Doctors endorse vegan and vegetarian diets for healthy pregnancies 2